Entasis Therapeutics Inc., of Waltham, Mass., said it completed a $50 million series B financing to advance its pipeline of clinical and preclinical products for treating major gram-negative infections. The financing was led by Clarus and included Frazier Healthcare Partners, Novo A/S, and Eventide Funds, who joined founding investor Astrazeneca plc.